May 4, 20210 min readNew Treatment Option for Relapsed/Refractory Marginal Zone and Follicular Lymphoma ~ 6/10/2021TG flyer.pdfDownload PDF • 103KB
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3
![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Comments